Gyre Therapeutics vs Niagen Bioscience
Gyre Therapeutics and Niagen Bioscience are similar in size: $117m and $129m of revenue in their latest fiscal years. Niagen Bioscience grew faster (29.9% against 10.2%). Niagen Bioscience kept more of each dollar of sales as profit: a net margin of 13.4% against 8.5%.
| Latest fiscal year | Gyre TherapeuticsGYRE, 2025 | Niagen BioscienceNAGE, 2025 |
|---|---|---|
| Revenue | $117m | $129m |
| Revenue growth | 10.2% | 29.9% |
| Net income | $9.9m | $17.4m |
| Operating margin | — | — |
| Net margin | 8.5% | 13.4% |
| Return on equity | 15.7% | 28.3% |
| Free cash flow | −$180,000 | $13.5m |
| Cash | $49.2m | $64.8m |
| Total debt | $0 | $0 |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $251,000 |
| Employees | — | — |
| Market value | $472m | $185m |
| Price vs our value range | — | Within our value range |
| Moat score | 9 (Weak) | 27 (Weak) |
| Insider trades, 12 months | 0 buys, 18 sales | 2 buys, 0 sales |